The Asia Pacific Dystonia Drugs Market should witness market growth of 6.2% CAGR during the forecast period (2022-2028).
DYT6 dystonia has been linked to chromosome 8 as an autosomal dominant primary dystonia (8p21q22). The disorder originates at a single site in nearly all individuals with this form of dystonia. Still, it extends to various body regions, most frequently the limbs, head, and neck. In addition, substantial articulation difficulties have been seen. Other known familial primary dystonia includes DYT7, DYT2, and DYT4, all of which have been observed in specific ethnic populations, primarily of European heritage.
The majority of secondary (symptomatic) effects stem from secondary causes. These include environmental factors, such as exposure to carbon monoxide, cyanide, manganese, or methanol; underlying conditions and diseases, such as brain tumors, cerebral palsy, Parkinson's disease, stroke, multiple sclerosis, hypoparathyroidism, or vascular malformations; brain/spinal cord injuries; inflammatory, infectious, or post-infectious brain disorders; and specific medications. Sometimes, dystonia is misdiagnosed as stress, a stiff neck, or a mental condition. The intermittent condition may lead doctors to assume that a psychological disorder is a primary cause or a contributing element. Dystonia is challenging to diagnose since its symptoms resemble numerous other illnesses and are changeable.
A universal primary health care system that offers everyone safe, efficient, practical, and inexpensive health services are the overall goal of China's health reform. In addition, health finance policies ensure that financial resources are used wisely and that all population groups, notably the most vulnerable and high-risk ones, have access to reasonably priced healthcare. Around 95% of people in China have access to the basic health insurance system. In 2018, the National Healthcare Security Administration was established to oversee China's health insurance programs. It offers chances to further boost the effectiveness of the healthcare system in terms of cost reduction, service quality, and better value for money. Hence, the constant development of the healthcare system will increase the availability of dystonia drugs, which will aid in the market expansion in the region.
The China market dominated the Asia Pacific Dystonia Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $85.9 Million by 2028. The Japan market is estimated to grow a CAGR of 5.6% during (2022-2028). Additionally, The India market would experience a CAGR of 6.9% during (2022-2028).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Type, the market is segmented into GABAergic Agents, Dopaminergic Agents, Anticonvulsants Drugs and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), Amneal Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, and Wellona Pharma.
DYT6 dystonia has been linked to chromosome 8 as an autosomal dominant primary dystonia (8p21q22). The disorder originates at a single site in nearly all individuals with this form of dystonia. Still, it extends to various body regions, most frequently the limbs, head, and neck. In addition, substantial articulation difficulties have been seen. Other known familial primary dystonia includes DYT7, DYT2, and DYT4, all of which have been observed in specific ethnic populations, primarily of European heritage.
The majority of secondary (symptomatic) effects stem from secondary causes. These include environmental factors, such as exposure to carbon monoxide, cyanide, manganese, or methanol; underlying conditions and diseases, such as brain tumors, cerebral palsy, Parkinson's disease, stroke, multiple sclerosis, hypoparathyroidism, or vascular malformations; brain/spinal cord injuries; inflammatory, infectious, or post-infectious brain disorders; and specific medications. Sometimes, dystonia is misdiagnosed as stress, a stiff neck, or a mental condition. The intermittent condition may lead doctors to assume that a psychological disorder is a primary cause or a contributing element. Dystonia is challenging to diagnose since its symptoms resemble numerous other illnesses and are changeable.
A universal primary health care system that offers everyone safe, efficient, practical, and inexpensive health services are the overall goal of China's health reform. In addition, health finance policies ensure that financial resources are used wisely and that all population groups, notably the most vulnerable and high-risk ones, have access to reasonably priced healthcare. Around 95% of people in China have access to the basic health insurance system. In 2018, the National Healthcare Security Administration was established to oversee China's health insurance programs. It offers chances to further boost the effectiveness of the healthcare system in terms of cost reduction, service quality, and better value for money. Hence, the constant development of the healthcare system will increase the availability of dystonia drugs, which will aid in the market expansion in the region.
The China market dominated the Asia Pacific Dystonia Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $85.9 Million by 2028. The Japan market is estimated to grow a CAGR of 5.6% during (2022-2028). Additionally, The India market would experience a CAGR of 6.9% during (2022-2028).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Type, the market is segmented into GABAergic Agents, Dopaminergic Agents, Anticonvulsants Drugs and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), Amneal Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, and Wellona Pharma.
Scope of the Study
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Route of Administration
- Oral
- Injectable
By Type
- GABAergic Agents
- Dopaminergic Agents
- Anticonvulsants Drugs
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Pfizer, Inc.
- Novartis AG
- Teva Pharmaceuticals Industries Ltd.
- AbbVie, Inc.
- F.Hoffmann-La Roche Ltd.
- Ipsen Pharma Biotech SAS
- Hameln Pharma Gmbh (Siegfried Group, LLP)
- Amneal Pharmaceuticals, Inc.
- Merz Pharma GmbH & Co. KGaA
- Wellona Pharma
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Dystonia Drugs Market, by Distribution Channel
1.4.2 Asia Pacific Dystonia Drugs Market, by Route of Administration
1.4.3 Asia Pacific Dystonia Drugs Market, by Type
1.4.4 Asia Pacific Dystonia Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Dystonia Drugs Market by Distribution Channel
3.1 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
3.2 Asia Pacific Hospital Pharmacies Market by Country
3.3 Asia Pacific Online Providers Market by Country
Chapter 4. Asia Pacific Dystonia Drugs Market by Route of Administration
4.1 Asia Pacific Oral Market by Country
4.2 Asia Pacific Injectable Market by Country
Chapter 5. Asia Pacific Dystonia Drugs Market by Type
5.1 Asia Pacific GABAergic Agents Market by Country
5.2 Asia Pacific Dopaminergic Agents Market by Country
5.3 Asia Pacific Anticonvulsants Drugs Market by Country
5.4 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Dystonia Drugs Market by Country
6.1 China Dystonia Drugs Market
6.1.1 China Dystonia Drugs Market by Distribution Channel
6.1.2 China Dystonia Drugs Market by Route of Administration
6.1.3 China Dystonia Drugs Market by Type
6.2 Japan Dystonia Drugs Market
6.2.1 Japan Dystonia Drugs Market by Distribution Channel
6.2.2 Japan Dystonia Drugs Market by Route of Administration
6.2.3 Japan Dystonia Drugs Market by Type
6.3 India Dystonia Drugs Market
6.3.1 India Dystonia Drugs Market by Distribution Channel
6.3.2 India Dystonia Drugs Market by Route of Administration
6.3.3 India Dystonia Drugs Market by Type
6.4 South Korea Dystonia Drugs Market
6.4.1 South Korea Dystonia Drugs Market by Distribution Channel
6.4.2 South Korea Dystonia Drugs Market by Route of Administration
6.4.3 South Korea Dystonia Drugs Market by Type
6.5 Singapore Dystonia Drugs Market
6.5.1 Singapore Dystonia Drugs Market by Distribution Channel
6.5.2 Singapore Dystonia Drugs Market by Route of Administration
6.5.3 Singapore Dystonia Drugs Market by Type
6.6 Malaysia Dystonia Drugs Market
6.6.1 Malaysia Dystonia Drugs Market by Distribution Channel
6.6.2 Malaysia Dystonia Drugs Market by Route of Administration
6.6.3 Malaysia Dystonia Drugs Market by Type
6.7 Rest of Asia Pacific Dystonia Drugs Market
6.7.1 Rest of Asia Pacific Dystonia Drugs Market by Distribution Channel
6.7.2 Rest of Asia Pacific Dystonia Drugs Market by Route of Administration
6.7.3 Rest of Asia Pacific Dystonia Drugs Market by Type
Chapter 7. Company Profiles
7.1 Pfizer, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional & Segmental Analysis
7.1.4 Research & Development Expense
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Teva Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.4 AbbVie, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Ipsen Pharma Biotech SAS
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Hameln Pharma Gmbh (Siegfried Group, LLP)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.8 Amneal Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expenses
7.9 Merz Pharma GmbH & Co. KGaA
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Approvals and Trials:
7.10. Wellona Pharma
7.10.1 Company Overview
Companies Mentioned
- Pfizer, Inc.
- Novartis AG
- Teva Pharmaceuticals Industries Ltd.
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Ipsen Pharma Biotech SAS
- Hameln Pharma Gmbh (Siegfried Group, LLP)
- Amneal Pharmaceuticals, Inc.
- Merz Pharma GmbH & Co. KGaA
- Wellona Pharma
Methodology
LOADING...
